Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16575
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCabarkapa, Sonja-
dc.contributor.authorPerera, Marlon-
dc.contributor.authorMcGrath, Shannon-
dc.contributor.authorLawrentschuk, Nathan-
dc.date2016-10-08-
dc.date.accessioned2017-02-12T22:07:16Z-
dc.date.available2017-02-12T22:07:16Z-
dc.date.issued2016-12-
dc.identifier.citationProstate International 2016; 4(4): 125-129en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16575-
dc.description.abstractBACKGROUND: Prostate cancer remains the most common non-skin cancer malignancy in men. Prostate-specific antigen (PSA) is recognized as a biomarker for the diagnosis, monitoring, and risk prediction of prostate cancer. Its use in the setting of prostate cancer screening has been controversial due to the risk of over diagnosis and over treatment. OBJECTIVE: Within Australia, there are inconsistent recommendations surrounding the use of PSA screening in clinical practice. In light of the 2016 PSA-screening guidelines by the major Australian health authorities, the current review aims to highlight the controversies and objectively outline the current recommendations within Australia. DISCUSSION: Health-care authorities across Australia have issued conflicting guidelines for prostate cancer screening culminating in confusion amongst health care practitioners and members of the public alike. A general consensus is held by other countries across the globe but differences amongst the specific details in how to best employ a PSA screening program still exist.en_US
dc.subjectGuidelinesen_US
dc.subjectProstate canceren_US
dc.subjectProstate-specific antigenen_US
dc.subjectScreeningen_US
dc.titleProstate cancer screening with prostate-specific antigen: a guide to the guidelinesen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleProstate Internationalen_US
dc.identifier.affiliationUniversity of Melbourne, Department of Surgery, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27995110en_US
dc.identifier.doi10.1016/j.prnil.2016.09.002en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-8553-5618en_US
dc.type.austinJournal Articleen_US
local.name.researcherMcGrath, Shannon
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptSurgery-
crisitem.author.deptUrology-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

46
checked on Nov 6, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.